Short-time homomorphic wavelet estimation

Successful wavelet estimation is an essential step for seismic methods like impedance inversion, analysis of amplitude variations with offset and full waveform inversion. Homomorphic deconvolution has long intrigued as a potentially elegant solution to the wavelet estimation problem. Yet a successful implementation has proven difficult. Associated disadvantages like phase unwrapping and restrictions of sparsity in the reflectivity function limit its application. We explore short-time homomorphic wavelet estimation as a combination of the classical homomorphic analysis and log-spectral averaging. The introduced method of log-spectral averaging using a short-term Fourier transform increases the number of sample points, thus reducing estimation variances. We apply the developed method on synthetic and real data examples and demonstrate good performance.Comment: 13 pages, 5 figures. 2012 J. Geophys. Eng. 9 67

Cross-Reactive Sensor Array for Metal Ion Sensing Based on Fluorescent SAMs\ud

Fluorescent self assembled monolayers (SAMs) on glass were previouslydeveloped in our group as new sensing materials for metal ions. These fluorescent SAMs arecomprised by fluorophores and small molecules sequentially deposited on a monolayer onglass. The preorganization provided by the surface avoids the need for complex receptordesign, allowing for a combinatorial approach to sensing systems based on small molecules.Now we show the fabrication of an effective microarray for the screening of metal ions andthe properties of the sensing SAMs. A collection of fluorescent sensing SAMs wasgenerated by combinatorial methods and immobilized on the glass surfaces of a custom-made 140 well microtiter-plate. The resulting libraries are easily measured and show variedresponses to a series cations such as Cu2+ , Co2+ , Pb2+ , Ca2+ and Zn2+ . These surfaces are notdesigned to complex selectively a unique analyte but rather they are intended to producefingerprint type responses to a range of analytes by less specific interactions. The unselectiveresponses of the library to the presence of different cations generate a characteristic patternfor each analyte, a “finger print” response.\u

Dense molecular gas toward W49A: A template for extragalactic starbursts?

The HCN, HCO+, and HNC molecules are commonly used as tracers of dense star-forming gas in external galaxies, but such observations are spatially unresolved. Reliably inferring the properties of galactic nuclei and disks requires detailed studies of sources whose structure is spatially resolved. We compare the spatial distributions and abundance ratios of HCN, HCO+, and HNC in W49A, the most massive and luminous star-forming region in the Galactic disk, based on maps of a 2' (6.6 pc) field at 14" (0.83 pc) resolution of the J=4-3 transitions of HCN, H13CN, HC15N, HCO+, H13CO+, HC18O+ and HNC. The kinematics of the molecular gas in W49A appears complex, with a mixture of infall and outflow motions. Both the line profiles and comparison of the main and rarer species show that the main species are optically thick. Two 'clumps' of infalling gas appear to be at ~40 K, compared to ~100 K at the source centre, and may be ~10x denser than the rest of the outer cloud. Chemical modelling suggests that the HCN/HNC ratio probes the current gas temperature, while the HCN/HCO+ ratio and the deuterium fractionation were set during an earlier, colder phase of evolution. The data suggest that W49A is an appropriate analogue of an extragalactic star forming region. Our data show that the use of HCN/HNC/HCO+ line ratios as proxies for the abundance ratios is incorrect for W49A, suggesting the same for galactic nuclei. Our observed isotopic line ratios such as H13CN/H13CO+ approach our modeled abundance ratios quite well in W49A. The 4-3 lines of HCN and HCO+ are much better tracers of the dense star-forming gas in W49A than the 1-0 lines. Our observed HCN/HNC and HCN/HCO+ ratios in W49A are inconsistent with homogeneous PDR or XDR models, indicating that irradiation hardly affects the gas chemistry in W49A. Overall, the W49A region appears to be a useful template for starburst galaxies.Comment: Accepted by A&A; 17 pages, 15 figure

Molecules as tracers of galaxy evolution: an EMIR survey. I. Presentation of the data and first results

We investigate the molecular gas properties of a sample of 23 galaxies in order to find and test chemical signatures of galaxy evolution and to compare them to IR evolutionary tracers. Observation at 3 mm wavelengths were obtained with the EMIR broadband receiver, mounted on the IRAM 30 m telescope on Pico Veleta, Spain. We compare the emission of the main molecular species with existing models of chemical evolution by means of line intensity ratios diagrams and principal component analysis. We detect molecular emission in 19 galaxies in two 8 GHz-wide bands centred at 88 and 112 GHz. The main detected transitions are the J=1-0 lines of CO, 13CO, HCN, HNC, HCO+, CN, and C2H. We also detect HC3N J=10-9 in the galaxies IRAS 17208, IC 860, NGC 4418, NGC 7771, and NGC 1068. The only HC3N detections are in objects with HCO+/HCN<1 and warm IRAS colours. Galaxies with the highest HC3N/HCN ratios have warm IRAS colours (60/100 {\mu}m>0.8). The brightest HC3N emission is found in IC 860, where we also detect the molecule in its vibrationally excited state.We find low HNC/HCN line ratios (<0.5), that cannot be explained by existing PDR or XDR chemical models. Bright HC3N emission in HCO+-faint objects may imply that these are not dominated by X-ray chemistry. Thus the HCN/HCO+ line ratio is not, by itself, a reliable tracer of XDRs. Bright HC3N and faint HCO+ could be signatures of embedded starformation, instead of AGN activity

Late onset of new conduction disturbances requiring permanent pacemaker implantation following TAVI

Background: The timing of onset and associated predictors of late new conduction disturbances (CDs) leading to permanent pacemaker implantation (PPI) following transcatheter aortic valve implantation (TAVI) are still unknown, however, essential for an early and safe discharge. This study aimed to investigate the timing of onset and associated predictors of late onset CDs in patients requiring PPI (LCP) following TAVI. Methods and results: We performed retrospective analysis of prospectively collected data from five large volume centres in Europe. Post-TAVI electrocardiograms and telemetry data were evaluated in patients with a PPI post-TAVI to identify the onset of new advanced CDs. Early onset CDs were defined as within 48 hours after procedure, and late onset CDs as after 48 hours. A total of 2804 patients were included for analysis. The PPI rate was 12%, of which 18% was due to late onset CDs (>48 hours). Independent predictors for LCP were pre-existing non-specific intraventricular conduction delay, pre-existing right bundle branch block, self-expandable valves and predilation. At least one of these risk factors was present in 98% of patients with LCP. Patients with a balloon-expandable valve without predilation did not develop CDs requiring PPI after 48 hours. Conclusions: Safe early discharge might be feasible in patients without CDs in the first 48 hours after TAVI if no risk factors for LCP are present

Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals

To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI). For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI. The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively. Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approac

Prespecified Risk Criteria Facilitate Adequate Discharge and Long-Term Outcomes After Transfemoral Transcatheter Aortic Valve Implantation

Background Despite the availability of guidelines for the performance of transcatheter aortic valve implantation (TAVI), current treatment pathways vary between countries and institutions, which impact on the mean duration of postprocedure hospitalization. Methods and Results This was a prospective, multicenter registry of 502 patients to validate the appropriateness of discharge timing after transfemoral TAVI, using prespecified risk criteria from FAST-TAVI (Feasibility and Safety of Early Discharge After Transfemoral [TF] Transcatheter Aortic Valve Implantation), based on hospital events within 1-year after discharge. The end point-a composite of all-cause mortality, vascular access-related complications, permanent pacemaker implantation, stroke, cardiac rehospitalization, kidney failure, and major bleeding-was reached in 27.0% of patients (95% CI, 23.3-31.2) within 1 year after intervention; 7.5% (95% CI, 5.5-10.2) had in-hospital complications before discharge and 19.6% (95% CI, 16.3-23.4) within 1 year after discharge. Overall mortality within 1 year after discharge was 7.3% and rates of cardiac rehospitalization 13.5%, permanent pacemaker implantation 4.2%, any stroke 1.8%, vascular-access-related complications 0.7%, life-threatening bleeding 0.7%, and kidney failure 0.4%. Composite events within 1 year after discharge were observed in 18.8% and 24.3% of patients with low risk of complications/early (≤3&nbsp;days) discharge and high risk and discharged late (&gt;3&nbsp;days) (concordant discharge), respectively. Event rate in patients with discordant discharge was 14.3% with low risk but discharged late and increased to 50.0% in patients with high risk but discharged in ≤3&nbsp;days. Conclusions The FAST-TAVI risk assessment provides a tool for appropriate, risk-based discharge that was validated with the 1-year event rate after transfemoral TAVI. Registration URL: https://www.ClinicalTrials.gov; Unique identifier: NCT02404467

Search for radiative pumping lines of OH masers: I. The 34.6um absorption line towards 1612 MHz OH maser sources

The 1612 MHz hydroxyl maser in circumstellar envelopes has long been thought to be pumped by 34.6um photons. Only recently, the Infrared Space Observatory has made possible spectroscopic observations which enable the direct confirmation of this pumping mechanism in a few cases. To look for the presence of this pumping line, we have searched the Infrared Space Observatory Data Archive and found 178 spectra with data around 34.6um for 87 galactic 1612MHz masers. The analysis performed showed that the noise level and the spectral resolution of the spectra are the most important factors affecting the detection of the 34.6um absorption line. Only 5 objects from the sample (3 red supergiants and 2 galactic center sources) are found to show clear 34.6um absorption (all of them already known) while two additional objects only tentatively show this line. The 3 supergiants show similar pump rates and their masers might be purely radiatively pumped. The pump rates of OH masers in late type stars are found to be about 0.05, only 1/5 of the theoretical value of 0.25 derived by Elitzur (1992). We have also found 16 maser sources which, according to the analysis assuming Elitzur's pump rate, should show the 34.6 $\mu$m absorption line but do not. These non-detections can be tentatively explained by far-infrared photon pumping, clumpy nature of the OH masing region or a limb-filling emission effect in the OH shell.Comment: 11 pages, 8 figures, 3 table

Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation

Percutaneous mitral valve repair with the MitraClip is an established treatment for patients with mitral regurgitation (MR) who are inoperable or at high risk for surgery. Atrial Fibrillation (AF) frequently coincides with MR, but only scarce data of the influence of AF on outcome after MitraClip is available. The aim of the current study was to compare the clinical outcome after MitraClip treatment in patients with versus without atrial fibrillation. Between January 2009 and January 2016, all consecutive patients treated with a MitraClip in 5 Dutch centers were included. Outcome measures were survival, symptoms, MR grade, and stroke incidence. In total, 618 patients were treated with a MitraClip. Patients with AF were older, had higher N-terminal B-type natriuretic peptide levels, more tricuspid regurgitation, less often coronary artery disease and a better left ventricular function. Survival of patients treated with the MitraClip was similar for patients with AF (82%) and without AF (non-AF; 85%) after 1 year (p = 0.30), but significantly different after 5-year follow-up (AF 34%; non-AF 47%; p = 0.006). After 1 month, 64% of the patients with AF were in New York Heart Association class I or II, in contrast to 77% of the patients without AF (p = 0.001). The stroke incidence appeared not to be significantly different (AF 1.8%; non-AF 1.0%; p = 0.40). In conclusion, patients with AF had similar 1-year survival, MR reduction, and stroke incidence compared with non-AF patients. However, MitraClip patients with AF had reduced long-term survival and remained more symptomatic compared with those without AF.</p

Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation

BACKGROUND The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied. METHODS In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI and did not have an indication for long-term anticoagulation, in a 1:1 ratio, to receive aspirin alone or aspirin plus clopidogrel for 3 months. The two primary outcomes were all bleeding (including minor, major, and life-threatening or disabling bleeding) and non-procedure-related bleeding over a period of 12 months. Most bleeding at the TAVI puncture site was counted as non-procedure-related. The two secondary outcomes were a composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or myocardial infarction (secondary composite 1) and a composite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2) at 1 year, with both outcomes tested sequentially for noninferiority (noninferiority margin, 7.5 percentage points) and superiority. RESULTS A total of 331 patients were assigned to receive aspirin alone and 334 were assigned to receive aspirin plus clopidogrel. A bleeding event occurred in 50 patients (15.1%) receiving aspirin alone and in 89 (26.6%) receiving aspirin plus clopidogrel (risk ratio, 0.57; 95% confidence interval [CI], 0.42 to 0.77; P=0.001). Non-procedure-related bleeding occurred in 50 patients (15.1%) and 83 patients (24.9%), respectively (risk ratio, 0.61; 95% CI, 0.44 to 0.83; P=0.005). A secondary composite 1 event occurred in 76 patients (23.0%) receiving aspirin alone and in 104 (31.1%) receiving aspirin plus clopidogrel (difference, −8.2 percentage points; 95% CI for noninferiority, −14.9 to −1.5; P<0.001; risk ratio, 0.74; 95% CI for superiority, 0.57 to 0.95; P=0.04). A secondary composite 2 event occurred in 32 patients (9.7%) and 33 patients (9.9%), respectively (difference, −0.2 percentage points; 95% CI for noninferiority, −4.7 to 4.3; P=0.004; risk ratio, 0.98; 95% CI for superiority, 0.62 to 1.55; P=0.93). A total of 44 patients (13.3%) and 32 (9.6%), respectively, received oral anticoagulation during the trial. CONCLUSIONS Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months